Amneal (AMRX) Director Buchi Exercises Options for 20,445 Shares

What Happened
Kevin J. Buchi, a director of Amneal Pharmaceuticals (AMRX), exercised stock options on September 11, 2026 to acquire 20,445 shares at an exercise price of $14.45 per share, for a total cash payment of $295,430. The Form 4 shows a corresponding derivative disposition for 20,445 shares at $0, reflecting the option being converted into common stock rather than a sale.

Key Details

• Transaction date: 2026-09-11 (reported on Form 4 filed 2026-09-14). Filing was within the routine reporting window.
• Action/code: M = Option exercise (derivative converted to common shares).
• Shares acquired: 20,445 shares at $14.45 each; total paid $295,430.
• Derivative disposition: 20,445 units reported disposed at $0 (represents the exercised option being removed).
• Footnote: F1 — the option was vested and exercisable at the time of exercise.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context
This was an option exercise resulting in an acquisition of shares (not a sale). The filing does not show an immediate sale of the shares (no cashless or sell-to-cover indicated), so Buchi appears to have converted vested options into common stock by paying the exercise price. Options exercises are common for executives/directors and reflect conversion of derivatives into stock rather than an open-market purchase or sale.